Table 2.
Criteria for Metabolic Syndrome in subjects with and without rheumatoid arthritis who did not have cardiovascular disease
| Criteria† | RA (n=232) | Non-RA (n=1241) | Odds Ratio (95% CI) | p-value |
|---|---|---|---|---|
| n (%) | n (%*) | Adjusted for age and sex | ||
| Elevated waist circumference | 127 (54) | 432 (35/40) | 2.3 (1.7, 3.1) | <0.001 |
| Elevated TG or treatment** | 64 (30) | 321 (35/28) | 0.8 (0.6, 1.2) | 0.26 |
| Reduced HDL or treatment** | 50 (24) | 198 (22/16) | 1.2 (0.8, 1.7) | 0.43 |
| Elevated blood pressure or treatment | 135 (58) | 725 (58/47) | 1.5 (1.1, 2.1) | 0.02 |
| Elevated fasting glucose or treatment*** | 64 (32) | 355 (37/28) | 1.0 (0.7, 1.4) | 0.96 |
| Metabolic Syndrome (≥3 of 5 criteria) | 76 (33) | 316 (25/20) | 1.6 (1.2, 2.2) | 0.002 |
MetS was defined using the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) criteria as affirmed and slightly modified by the American Heart Association (AHA) and the National Heart, Lung and Blood Institute (NHLBI) (14). The MetS definition requires any 3 of these 5 criteria: elevated waist circumference (≥102 cm in non-Asian men, ≥88 cm in non-Asian women, ≥90 cm in Asian men, ≥80 cm in Asian women), elevated triglycerides (TG ≥ 150 mg/dL or treatment with fibrates or nicotinic acid), reduced high-density cholesterol (HDL<40 mg/dL in men or <50 mg/dL in women or treatment with fibrates or nicotinic acid), elevated BP (≥130 mmHg systolic or ≥85 mmHg diastolic or treatment for hypertension) or elevated fasting glucose (FG ≥ 100 mg/dL or treatment for elevated glucose).
non-RA percentages are presented raw and adjusted to the age and sex distribution of the RA subjects.
lipid measures were not available in 21 RA and 324 non-RA subjects
glucose measures were not available in 35 RA and 284 non-RA subjects
RA = rheumatoid arthritis; TG = triglycerides; HDL = high-density cholesterol; CI = confidence interval